Lecanoric acid mediates anti-proliferative effects by an M phase arrest in colon cancer cells.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 12 01 2022
revised: 14 02 2022
accepted: 15 02 2022
pubmed: 23 2 2022
medline: 26 3 2022
entrez: 22 2 2022
Statut: ppublish

Résumé

Lichen extracts containing, among other compounds, depsides such as evernic acid, atranorin, and lecanoric acid possess anti-proliferative effects. We aimed to identify lichen metabolites that are responsible for the observed anti-proliferative effects. We performed cytotoxicity, cell colony, cell cycle and apoptosis assays in various cell lines or primary immune cells. We analyzed several cell cycle proteins and apoptosis-related proteins to gain insights into the underlying mechanism. All depsides reduced the viability of the tested cell lines (HCT-116, HEK293T, HeLa, NIH3T3, RAW246.7) in a cell line-dependent manner with lecanoric acid being the most effective. Atranorin did not influence the cell cycle or colony formation in HCT-116 cells, but induced apoptosis in HCT-116 cells. Evernic acid showed no anti-proliferative effects. Lecanoric acid inhibited cell colony formation already at 0.03 µg/ml in HCT-116 cells and induced a G2 cell cycle block in several cell lines. Moreover, lecanoric acid arrested the cell cycle, presumably in the M phase, since expression of cyclin B1 and phosphorylated histone H3 was upregulated, whereas the inactive cyclin-dependent kinase 1 (CDK1) was reduced in HCT-116 cells. Most importantly, cell death induced by lecanoric acid was more prominent in cancer cells than in primary human immune and endothelial cells. In conclusion, lecanoric acid seems to mediate its anti-proliferative effects via arrest of cells in the M phase. Our data suggest lecanoric acid may be a potential new candidate for anti-cancer therapy, because it has anti-proliferative effects on cancer cell lines, and does not affect primary immune cells.

Identifiants

pubmed: 35190352
pii: S0753-3322(22)00122-6
doi: 10.1016/j.biopha.2022.112734
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Cyclin B1 0
Histones 0
Hydroxybenzoates 0
Salicylates 0
atranorin 450U2VJ2VG
lecanoric acid 480-56-8
evernic acid 537-09-7
CDC2 Protein Kinase EC 2.7.11.22
CDK1 protein, human EC 2.7.11.22

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112734

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Luise A Roser (LA)

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany; LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany.

Pelin Erkoc (P)

LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany; Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany.

Rebecca Ingelfinger (R)

LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany; Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany.

Marina Henke (M)

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany; LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany.

Thomas Ulshöfer (T)

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany; LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany.

Ann-Kathrin Schneider (AK)

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany.

Volker Laux (V)

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany.

Gerd Geisslinger (G)

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany; LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany; Pharmazentrum Frankfurt/ZAFES, Department of Clinical Pharmacology, Goethe-University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.

Imke Schmitt (I)

LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany; Senckenberg Biodiversity and Climate Research Centre (SBiK-F), Senckenberganlage 25, D-60325 Frankfurt, Germany; Institute of Ecology, Evolution, and Diversity, Goethe University Frankfurt, Max-von-Laue-Str. 13, 60438 Frankfurt, Germany.

Robert Fürst (R)

LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany; Institute of Pharmaceutical Biology, Faculty of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany.

Susanne Schiffmann (S)

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany. Electronic address: susanne.schiffmann@itmp.fraunhofer.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH